ADAM23 Antibody

ADAM23 Antibody: Definition and Structure

ADAM23 Antibody is a polyclonal or monoclonal antibody that recognizes epitopes in the extracellular region of ADAM23. Key structural features include:

• Target Epitope: The extracellular disintegrin domain (e.g., residues 367–381 in mouse ADAM23) .

• Species Reactivity: Cross-reacts with human, mouse, rat, and avian orthologs .

• Antibody Types:

  • Polyclonal: Raised against full-length or peptide sequences (e.g., CSB-PA001285LA01HU) .

  • Monoclonal: Engineered for high specificity (e.g., MAB4974 from R&D Systems) .

Functional Roles of ADAM23 and Antibody Applications

ADAM23 interacts with integrins (e.g., αvβ3) via its disintegrin domain to regulate:

• Cell Adhesion: Promotes neural cell attachment (e.g., neuroblastoma, astrocytoma) .

• Immune Response: Modulates dendritic cell (DC)-T cell interactions, influencing T cell activation and cytokine production (IL-2, IFN-γ) .

• Cancer Suppression: Downregulated in cancer stem cells (side population), inhibiting metastasis via αvβ3 integrin modulation .

Key Research Findings

Immunohistochemistry (IHC)

• Detection: ADAM23 in human spleen (MAB4974) and mouse brain (ANR-155) .

• Protocol:

  1. Antigen retrieval with heat-induced epitope methods.

  2. Primary antibody incubation (1:200–1:500) .

  3. Visualization with HRP-conjugated secondary antibodies .

Western Blotting

• Sample Preparation: Rat/mouse brain membranes or THP-1 cell lysates .

• Blocking Peptide Validation: Pre-incubation with blocking peptide (e.g., BLP-NR155) abolishes ADAM23 detection .

Flow Cytometry

• Cell Surface Detection: Live THP-1 cells stained with ANR-155 + PE-conjugated secondary antibody .

Therapeutic and Diagnostic Potential

ADAM23 Antibody research highlights its utility in:

• Cancer Therapy: Epigenetic silencing of ADAM23 in breast cancer correlates with poor prognosis . Neutralizing antibodies may restore tumor suppression.

• Neurological Disorders: ADAM23 autoantibodies linked to autoimmune encephalitis; antibody-based diagnostics could identify pathological states .

• Cardiac Hypertrophy: ADAM23 overexpression in cardiomyocytes suppresses hypertrophy, suggesting therapeutic targeting .

Challenges and Future Directions

• Specificity: Cross-reactivity with related ADAM proteins requires careful validation.

• Clinical Translation: ADAM23’s role in epilepsy and cardiomyopathy warrants human trials.

• Mechanistic Studies: Elucidating ADAM23’s interaction with lipid rafts and Kv1 channels .